Oncolytics Biotech (TSE:ONC) Stock Price Up 14.5% – What’s Next?

Oncolytics Biotech Inc. (TSE:ONC) shares traded up 14.5% on Thursday . The stock traded as high as C$1.26 and last traded at C$1.26. 243,945 shares were traded during trading, an increase of 230% from the average session volume of 73,919 shares. The stock had previously closed at C$1.10.

Analysts Set New Price Targets

Separately, Raymond James raised shares of Oncolytics Biotech to a “moderate buy” rating in a research report on Thursday, November 14th.

Oncolytics Biotech Price Performance

The company’s 50-day simple moving average is C$1.45 and its 200 day simple moving average is C$1.40. The company has a quick ratio of 8.86, a current ratio of 4.99 and a debt-to-equity ratio of 6.09. The stock has a market capitalization of C$91.46 million, a price-to-earnings ratio of -3.13 and a beta of 1.35.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.